Intranasal Aβ1-6 A2V Peptide for Tau Aggregation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, particularly those related to tau protein misfolding and aggregation, are inadequate as they often target single pathways without considering the complexity of the disorder, and there is a lack of effective strategies for delivering therapeutic agents across the blood-brain barrier.
Innovation Solution
The hexapeptide Aβ1-6 A2V (D) is administered intranasally, allowing high brain penetration without the need for blood-brain-barrier carriers, and interferes with tau-related processes by inhibiting Aβ1-42 oligomers binding to tau, hindering tau polymerization, and reducing oxidative stress, providing a multi-target approach to treat or prevent tau-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional pharmacological approaches are used to treat tau-related disorders, then single-target pathways are addressed, but the complexity of the disorder remains unmanaged and treatment effectiveness is limited
Solution Approach 1:
The patent employs a peptide library system where a single platform can screen for multiple targets simultaneously. The phage-displayed peptide library is designed to identify compounds that can bind to various tau-related proteins and pathways, enabling one therapeutic agent to address multiple disease mechanisms rather than requiring separate single-target drugs for each pathway
Solution Approach 2:
The patent segments the complex tauopathy disease process into distinct targetable components (tau aggregation, oxidative stress, synaptic dysfunction, amyloid plaque formation) and uses the peptide library to identify compounds that can address multiple segments simultaneously, transforming an unmanageable complex disorder into addressable discrete targets
2Reliability
If therapeutic agents are administered to cross the blood-brain barrier, then brain delivery is achieved, but the need for specialized carriers increases treatment complexity
Solution Approach 1:
The patent identifies peptide compounds that possess intrinsic ability to cross the blood-brain barrier without requiring external carrier systems. The screened peptides are selected based on their own structural properties that enable passive or active transport across the barrier, allowing the therapeutic agent to serve its own delivery function rather than relying on complex engineered carriers
3Object-affected harmful factors
If tau protein misfolding and aggregation are targeted, then neurodegeneration is prevented, but single-pathway approaches fail to address the multi-factor nature of the disorder
Solution Approach 1:
The patent merges multiple disease-modifying activities into a single peptide therapeutic candidate. The screening system identifies compounds that simultaneously address tau aggregation, oxidative stress, and synaptic dysfunction, combining what would traditionally require multiple separate treatments into one multi-functional agent that covers the multi-factor nature of the disorder
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
Tau protein misfolding, aggregation and accumulation in the nervous system is an abnormal event which is responsible for widespread synaptic loss and neurodegeneration; it can occur spontaneously or can be triggered by misfolding of amyloid β protein. The present invention concerns the use of hexapeptide Aβ1-6A2V(D) in the treatment of a family of neurodegenerative diseases related to tau pathology. In the present studies, Aβ1-6A2V(D) is shown capable of interfering with protein tau at different levels. This property, in association with additional neuroprotective activities of Aβ1-6A2V(D), offers as a whole an excellent therapeutic asset against tau protein-related diseases. Moreover, the intranasal administration of Aβ1-6A2V(D) obtains remarkable levels of permeation of this peptide through the blood-brain barrier, with widespread distribution thereof among the most important brain areas involved in tau pathology.